Achieve Life Sciences (ACHV) investor relations material

Company overview and business model

• Focuses on addressing nicotine dependence through development and commercialization of cytisinicline, targeting both combustible cigarette and e-cigarette users in the U.S. and globally.

• Operates as a late-stage clinical specialty pharmaceutical company with a mission to reduce preventable deaths from tobacco use.

• Principal executive offices are located in Bothell, WA, and Vancouver, BC.

Financial performance and metrics

• As of September 30, 2025, 52,812,488 shares of common stock were issued and outstanding, with no preferred stock outstanding.

• 33,955,958 warrants outstanding with a weighted-average exercise price of $3.92 per share; 142,857 pre-funded warrants at $0.001 per share.

• 5,274,182 shares reserved for stock-based compensation plans, including options and restricted stock units.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including research, clinical and process development, manufacturing, commercialization, working capital, debt reduction, acquisitions, investments, and capital expenditures.

• Pending use, proceeds may be invested in short- or long-term investment-grade, interest-bearing securities.